An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Better Therapeutics (NASDAQ: BTTX) received its first patent from the USPTO, granting 20 years of exclusivity for key features of its digital therapeutics platform targeting cardiometabolic diseases. The patent, titled “SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN DIGITAL HEALTH THERAPEUTICS,” was awarded on June 7, 2022. This innovation enables the use of machine learning to personalize treatment regimens. The company plans to file for FDA approval of its first product, BT-001, for type 2 diabetes, following a pivotal clinical trial completion.
Positive
Granted a patent providing 20 years of exclusivity for core features of the digital therapeutics platform.
Patent covers innovative machine learning techniques for personalized treatment, enhancing treatment adherence and outcomes.
On track to file FDA submission for BT-001 after pivotal clinical trial completion.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company’s digital therapeutics platform, designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT.
“Our team has been on the cutting edge of using software to help individuals change the behaviors that are the underlying causes of cardiometabolic conditions like type 2 diabetes and fatty liver disease,” said Kevin Appelbaum, CEO of Better Therapeutics. “This work has resulted in a number of new and distinct inventions, and we are proud that this ingenuity has now been officially recognized by the USPTO.”
The new patent, U.S. Patent No. 11,355,228 granted on June 7th, 2022, is titled “SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN DIGITAL HEALTH THERAPEUTICS,” and covers methods and apparatus for generating and monitoring a therapy regimen employing Better Therapeutics’ innovative machine learning techniques. Taken together with the 510 days of patent term adjustment provided by the U.S. Patent and Trademark Office, Better Therapeutics’ exclusivity will extend until at least September of 2039, absent any further patent extensions.
The mechanisms covered in the patent are core to Better Therapeutics’ digital platform and relate to the way in which it uses machine learning and artificial intelligence to personalize treatment for each patient in order to optimize adherence and outcomes. Better Therapeutics remains on track to file its de novo submission to FDA for its first product - BT-001, a treatment for type 2 diabetes – following the completion of its pivotal clinical trial this month.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
